PDCD1 and neoplasm: The bifunctional proteins, particularly the TGF-β ligand Trap-anti-PD-1 mAb (i.e., Bintrafusp Alfa and SHR1701), designed to selectively neutralize TGF-βs 1 and 3 in tumors (targeted to tumors with the anti-PD-1 moiety) gave impressive tumor responses with acceptable safety profiles compared to standard checkpoint therapies.